All In Biotech

Drug Trial Radar · NCT01285323

A Study to Evaluate the Efficacy and Safety of Reslizumab in Patients With Eosinophilic Asthma

A 12-Month, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Reslizumab (3.0 mg/kg) in the Reduction of Clinical Asthma Exacerbations in Patients (12-75 Years of Age) With Eosinophilic Asthma

Last checked: Nov 20, 2026Latest source record: Nov 9, 2021 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 464 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

464

Actual

Start

Mar 2011

Primary completion

Apr 2014

Study completion Apr 2014

Sponsor

Sponsor type
Industry
First posted
Jan 28, 2011

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 12 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The primary objective of this study is to determine whether reslizumab is more effective than placebo in reducing the number of clinical asthma exacerbations (CAEs) in patients with eosinophilic asthma.

Conditions

  • Eosinophilic Asthma

Interventions

  • ReslizumabDrug

    Patients were administered intravenously over 15 to 30 minutes reslizumab at a dosage of 3.0 mg/kg at baseline and once every 4 weeks relative to baseline over 48 weeks for a total of 13 doses.

  • PlaceboDrug

    Matching placebo (acetate sucrose buffer), administered intravenously (iv) once every 4 weeks for a total of 13 doses.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Frequency of Clinical Asthma Exacerbations (CAEs) During 12 Months of TreatmentTime frame: Day 1 to Month 12
  2. Frequency of Each of the Two Criteria for Clinical Asthma Exacerbations (CAEs)Time frame: Day 1 to Month 12

Locations

104 sites in 15 countries. Site status is shown where the registry gives one.

  • Teva Investigational Site 48

    Mobile, Alabama

  • Teva Investigational Site 41

    Fresno, California

  • Teva Investigational Site 59

    Long Beach, California

  • Teva Investigational Site 47

    Denver, Colorado

  • Teva Investigational Site 28

    Waterbury, Connecticut

  • Teva Investigational Site 53

    Clearwater, Florida

  • Teva Investigational Site 27

    Miami, Florida

  • Teva Investigational Site 25

    Lawrenceville, Georgia

  • Teva Investigational Site 57

    Metairie, Louisiana

  • Teva Investigational Site 46

    Bangor, Maine

  • Teva Investigational Site 40

    St Louis, Missouri

  • Teva Investigational Site 67

    Fort Mill, South Carolina

  • Teva Investigational Site 44

    Dallas, Texas

  • Teva Investigational Site 69

    El Paso, Texas

  • Teva Investigational Site 45

    San Antonio, Texas

  • Teva Investigational Site 121

    Ciudad Autonoma de Buenos Aire, Argentina

  • Teva Investigational Site 126

    Ciudad Autonoma de Buenos Aire, Argentina

  • Teva Investigational Site 123

    Rosario-Santa Fe, Argentina

  • Teva Investigational Site 120

    San Miguel de Tucuman - Tucuma, Argentina

  • Teva Investigational Site 150

    Florianópolis, Brazil

  • Teva Investigational Site 140

    Porto Alegre, Brazil

  • Teva Investigational Site 144

    Porto Alegre, Brazil

  • Teva Investigational Site 145

    Porto Alegre, Brazil

  • Teva Investigational Site 143

    Porto Alegre, RS, Brazil

  • Teva Investigational Site 142

    Santo André, Brazil

  • Teva Investigational Site 104

    Newmarket, Canada

  • Teva Investigational Site 102

    Pointe-Claire, Canada

  • Teva Investigational Site 105

    Windsor, Canada

  • Teva Investigational Site 343

    Grenoble, France

  • Teva Investigational Site 342

    Marseille, France

  • Teva Investigational Site 341

    Montpellier, France

  • Teva Investigational Site 360

    Bad Wörishofen, Germany

  • Teva Investigational Site 361

    Berlin, Germany

  • Teva Investigational Site 362

    Berlin, Germany

  • Teva Investigational Site 366

    Berlin, Germany

  • Teva Investigational Site 371

    Bochum, Germany

  • Teva Investigational Site 365

    Dresden, Germany

  • Teva Investigational Site 369

    Frankfurt, Germany

  • Teva Investigational Site 370

    Hamburg, Germany

  • Teva Investigational Site 372

    Koblenz, Germany

Showing 40 of 104 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.